Full text is available at the source.
Abstract
Intravesically administered interleukin-12 mRNA-loaded lipid nanoparticles (IL-12 mRNA LNPs) may offer a new approach for treating bladder cancer.
- The study focuses on the feasibility of using IL-12 mRNA LNPs for bladder cancer treatment.
- This therapy targets orthotopic bladder cancer specifically.
- Interleukin-12, a cytokine, is known for its potential immune-boosting properties.
- The application method is designed to deliver the treatment directly to the bladder.
Simplified